George Panagis
Overview
Explore the profile of George Panagis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schmidt T, Rea E, Shababi-Klein J, Panagis G, Winter C
Int J Neuropsychopharmacol
. 2012 Oct;
16(5):1083-91.
PMID: 23043789
The underlying neurobiology of addictive or repetitive behaviours, such as obsessive-compulsive disorder (OCD), involves dopaminergic dysregulation. While addictive behaviour depends strongly on mesolimbocortical dopaminergic responses, repetitive behaviours have been associated...
12.
Katsidoni V, Anagnostou I, Panagis G
Addict Biol
. 2012 Aug;
18(2):286-96.
PMID: 22862835
Cannabidiol is a non-psychotomimetic constituent of Cannabis sativa, which induces central effects in rodents. It has been shown that cannabidiol attenuates cue-induced reinstatement of heroin seeking. However, to the best...
13.
Vivas A, Estevez A, Moreno M, Panagis G, Flores P
Hum Psychopharmacol
. 2012 Aug;
27(5):464-9.
PMID: 22859379
Objective: Orienting attention to an irrelevant location hampers the response to subsequent targets presented at that location in relation to novel, not previously attended, locations. This inhibitory effect has been...
14.
Katsidoni V, Apazoglou K, Panagis G
Psychopharmacology (Berl)
. 2010 Jun;
213(2-3):337-54.
PMID: 20577718
Rationale: The serotonin 5-HT(2A) and 5-HT(2C) receptors, which are found in abundance in the mesolimbocortical dopaminergic system, appear to modulate the behavioral effects of cocaine. Objectives: The present series of...
15.
Mavrikaki M, Markaki E, Nomikos G, Panagis G
Behav Brain Res
. 2010 Jan;
209(1):114-8.
PMID: 20097234
The present study sought to examine whether repeated administration of the CB(1) receptor agonist WIN55,212-2 affected intracranial self-stimulation (ICSS) behavior and induced phenomena of tolerance or sensitization, similar to typical...
16.
Mavrikaki M, Nomikos G, Panagis G
Int J Neuropsychopharmacol
. 2010 Jan;
13(4):541-8.
PMID: 20047715
The atypical antipsychotic aripiprazole has been demonstrated to reduce symptoms of bipolar mania. To further profile the antimanic-like properties of aripiprazole in relevant preclinical models, we examined its efficacy in...
17.
Messinis L, Lyros E, Andrian V, Katsakiori P, Panagis G, Georgiou V, et al.
Hum Psychopharmacol
. 2009 Aug;
24(7):524-31.
PMID: 19650155
Rationale: Methadone and buprenorphine are among the most widely employed pharmacological treatments currently available for opioid addiction. Cognitive effects of buprenorphine in abstinent heroin abusers are nevertheless far from being...
18.
Panagis G, Vlachou S, Nomikos G
Curr Drug Abuse Rev
. 2009 Jul;
1(3):350-74.
PMID: 19630731
Cannabis preparations as recreational drugs are the most widely used illicit drugs in the world. Although cannabis derivatives produce clear subjective motivational responses in humans leading to drug-seeking behavior and...
19.
Mavrikaki M, Nomikos G, Panagis G
Eur Neuropsychopharmacol
. 2008 Dec;
19(3):205-14.
PMID: 19110403
Bipolar disorder is characterized by dysregulated motivation and increased hedonistic drive. d-Amphetamine induces manic symptoms in humans and exacerbates mania in bipolar disorder patients, effects that are counteracted by mood...
20.
Vlachou S, Stamatopoulou F, Nomikos G, Panagis G
Int J Neuropsychopharmacol
. 2008 Apr;
11(7):905-23.
PMID: 18377702
Cannabinoids, in contrast to typical drugs of abuse, have been shown to exert complex effects on behavioural reinforcement and psychomotor function. We have shown that cannabinoid agonists lack reinforcing/rewarding properties...